Clinical Trial Update: A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST） [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Firmonertinib versus placebo as adjuvant therapy for stage IB-IIIB non-small cell lung cancer with uncommon EGFR mutations after surgic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Firmonertinib (firmonertinib)

Snippet

Sponsor: Allist Pharmaceuticals, Inc. | Conditions: NSCLC, Adjuvant Treatment | Phase 3 | Status: RECRUITING